Utilizing a measured approach can increase the probability for identifying search criteria that fulfill a company’s strategy.
Ranan Lachman
Advertisement
Articles by Ranan Lachman
Out-licensing has become a crucial part of most biotech companies' business strategies.
Companies should dig in a more attractive mine where very few other companies are looking.
Advertisement
Latest Updated Articles
Private Industry's Most EligiblePublished: October 1st 2004 | Updated:
The Art and Process of Successful In-LicensingPublished: June 1st 2005 | Updated:
The Top Five Drivers of a Successful Out-licensing ProcessPublished: April 1st 2005 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Regulatory Challenges for Global Manufacturing of Vaccines
2
AI-Driven Organ-on-Chip Platforms Are Changing the Game in Bio/Pharma R&D
3
EU Biopharma Strategy: Scaling Up to Tackle Funding Gaps and Drive Innovation
4
RNAnalytics’ Viktoria Enkmann Ponders Nanoparticle Characterization Advances at CPHI Frankfurt: Part One
5
